Protai utilizes machine learning and mass spectrometry-derived proteomics data to create a vertically integrated platform for drug discovery. This technology enables precise targeting of complex disease drivers, facilitating the identification of novel therapeutic targets and improving the development of effective treatments.
Funding
$20M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
GVPVFounders
Product
Problem
Current drug discovery methods often fail to address the complexity of diseases at the protein level, leading to ineffective treatments and a lack of precise therapeutic targets. Traditional approaches struggle to simulate disease on a molecular level, hindering the identification of novel drug candidates.
Solution
Protai offers a vertically integrated platform for drug discovery that leverages mass spectrometry-derived proteomics data and machine learning to simulate disease biology. The AIMS™ platform facilitates the identification of novel therapeutic targets and improves the development of effective treatments by precisely targeting complex disease drivers. By unlocking proteins in their native states, Protai transforms disease treatment through a deep understanding of protein networks, post-translational modifications, and complex structures. The platform integrates structural and functional proteomics data with AI to highlight innovative drug mechanisms and discover best-in-class drug candidates.
Target Audience
The primary customers are pharmaceutical companies and academic labs seeking to collaborate on drug discovery and development, target redefinition, and mechanism of action understanding.
Features
- AIMS™ platform integrates structural and functional mass spectrometry proteomics data and AI
- Identification of novel therapeutic targets
- Advanced protein simulations to discover novel best-in-class medicines
- Target redefinition, drug discovery and optimization, and deep MOA understanding
- Disease- and modality-agnostic pipeline
- Focus on validated drug targets in oncology and immunology